This clinical trial is for men and women with prostate-specific membrane antigen (PSMA)-positive metastatic castrate resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibitor (ARPI) and taxane-containing regimen, and who progressed on or after treatment with [177Lu]Lu-PSMA targeted therapy.
   
The purpose of the study is to determine if the new experimental drug AAA817 is safe and effective (can help people with prostate cancer) compared to standard treatments (SoC).
   

This study is for men and women who have undergone a liver transplant and have been diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a liver disease associated with fat buildup and inflammation in the liver. This study will test the investigational/study drug resmetirom.
   

This study is for men and women who have been diagnosed with primary biliary cholangitis (PBC), a chronic liver disease that slowly damages the bile ducts in the liver. This study will test the investigational/study drug Seladelpar.

Seladelpar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of PBC. However, this study is being conducted to further evaluate its safety and effectiveness.

This clinical trial is for adults who have advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal cancer.
   

We are collecting samples so they can be made available to future research scientists who hope to study the human body’s immune response to common infectious illness such as influenza or SARS-CoV-2. This means these samples can be used for other people’s research studies. Participants are healthy adults who have a history of coronavirus and/or influenza, vaccine history or lack thereof, and absence of immunocompromise. 
   

This clinical trial is for adults who have been diagnosed with a cancer called Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The purpose of this study is to test if BGB-16673 and pirtobrutinib are safe and test how well BGB-16673 compares to pirtobrutinib in participants with previously treated CLL or SLL. 
   
Participants will be randomly assigned (like the flip of a coin) to receive study treatment with either BGB-16673 (Arm A of the study) or pirtobrutinib (Arm B).
   

This clinical trial is for adults who have an advanced solid tumor that has been treated with approved standard therapy and who have experienced disease progression following this prior treatment. The advanced solid tumor must be either non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), or head and neck squamous cell carcinoma (HNSCC).
   

 This clinical trial is for adults who have a confirmed diagnosis of solid tumor cancer associated with a risk of recurrence or progression (meaning that the cancer could come back or worsen).
   

This clinical trial is for adults who have advanced gastric, esophageal, or gastroesophageal junction (GEJ) cancer. The purpose of this study is to learn if the experimental drug denikitug (DEN) can help to control advanced gastric, esophageal, or GEJ cancer. The study will test DEN by itself and combined with other cancer drugs.
   
The study has two parts:
   --In Part 1, participants will be randomized (chosen by chance, like flipping a coin) to receive DEN alone or in combination with nivolumab (NIVO).

The purpose of this study is to find out if researchers can lower the chance of non-muscle invasive bladder cancer growing or spreading by using a combination of drugs called durvalumab and monalizumab. 
   
This combination of drugs has been tested in people with other cancers and was found to stabilize the cancer and stop it from spreading. However, the combination of durvalumab and monalizumab has not been tested in non-muscle invasive bladder cancer.